INNOVAPATH™
The Premier Journal Bridging Discovery & Innovation

Review Article
https://doi.org/10.63501/hw12ag67

Neonatal Hypoxic-Ischemic Encephalopathy: Pathophysiology, Neuroprotective Strategies, and Long-Term Neurodevelopmental Outcomes

Abdul Hannan Asghar[1,5], Haram Fatima[2], Aon Abbas[1], Laiba Munawar[3], Mehr un Nissa[1], Momina Niazi[4]

[1]Quaid-e-Azam Medical College, Bahawalpur

[2]Fatima Jinnah Medical University Lahore

[3]Islam Medical and Dental College Sialkot

[4]Services Institute of Medical Sciences

[5]Corresponding Author Email: Hannana260@gmail.com

ABSTRACT:

Neonatal hypoxic-ischemic encephalopathy (HIE) is a major cause of neonatal mortality and long-term neurodevelopmental disability worldwide, particularly in low- and middle-income countries. It results from impaired cerebral perfusion and oxygen delivery during the perinatal period, initiating a complex and evolving cascade of metabolic failure, excitotoxicity, oxidative stress, inflammation, and cell death. The pathophysiology of HIE is now understood as a dynamic process comprising primary energy failure, a latent phase, secondary injury, and a prolonged tertiary phase characterized by chronic neuroinflammation and impaired brain repair. This evolving understanding has led to the identification of critical therapeutic windows for intervention.

Therapeutic hypothermia remains the cornerstone of treatment and has significantly reduced mortality and neurodevelopmental impairment in infants with moderate to severe HIE. However, its neuroprotective effects are incomplete, and a substantial proportion of survivors continue to experience adverse outcomes, including cerebral palsy, epilepsy, cognitive deficits, and behavioral disorders. Consequently, there is growing interest in adjunctive neuroprotective strategies targeting multiple pathways of injury. Emerging therapies such as erythropoietin, melatonin, allopurinol, and stem cell-based interventions have demonstrated promising neuroprotective potential in preclinical and early clinical studies.

Advances in neuroimaging, electrophysiological monitoring, and biomarker discovery are improving early diagnosis, risk stratification, and prognostication. Despite these developments, significant challenges remain, particularly in resource-limited settings where access to timely and effective interventions is constrained. A comprehensive approach integrating early identification, multimodal neuroprotection, and long-term neurodevelopmental follow-up is essential. Continued research focusing on precision medicine, combination therapies, and equitable healthcare delivery will be critical to improving outcomes for infants affected by HIE.

Review Article
https://doi.org/10.63501/hw12ag67

INTRODUCTION:

Neonatal hypoxic-ischemic encephalopathy (HIE) is a serious and often devastating neurological condition resulting from impaired cerebral perfusion and oxygen delivery during the perinatal period. It represents one of the leading causes of neonatal mortality and long-term neurodevelopmental disability worldwide, particularly in low- and middle-income countries where access to timely obstetric and neonatal care remains limited (1)(3). Clinically, HIE is characterized by a constellation of neurological abnormalities, including altered consciousness, hypotonia or hypertonia, seizures, and impaired reflexes, typically manifesting within the first hours to days of life (1).

The global burden of HIE remains substantial, with an estimated incidence of 1–3 per 1,000 live births in high-income settings, rising to 10–20 per 1,000 live births in resource-limited regions (2)(3). These disparities reflect differences in perinatal care, including delays in recognizing fetal distress, limited access to emergency obstetric interventions, and inadequate neonatal resuscitation facilities. Importantly, even in well-resourced healthcare systems, HIE continues to contribute significantly to neonatal intensive care admissions and long-term morbidity.

The pathogenesis of HIE is complex and multifactorial, involving a sequence of events that begins with an acute hypoxic-ischemic insult and evolves over time into a cascade of secondary and tertiary injury processes. Historically, HIE was viewed as a single, acute event; however, advances in experimental and clinical research have redefined it as a dynamic and evolving condition with multiple therapeutic windows (4)(7). The initial phase of energy failure is followed by a latent period and subsequent secondary deterioration, characterized by excitotoxicity, oxidative stress, mitochondrial dysfunction, and inflammation. More recently, a tertiary phase involving chronic neuroinflammation and impaired brain repair mechanisms has been recognized, further contributing to long-term neurological sequelae (7).

Over the past two decades, the introduction of therapeutic hypothermia has marked a major milestone in the management of HIE. By targeting key pathways in the secondary phase of injury, hypothermia has been shown to reduce mortality and improve neurodevelopmental outcomes in infants with moderate to severe encephalopathy (10). Nevertheless, its protective effects are incomplete, with a significant proportion of treated infants still developing adverse outcomes, including cerebral palsy, epilepsy, and cognitive impairment (12). This underscores the need for adjunctive therapies and a deeper understanding of the underlying mechanisms of injury.

In parallel, there has been growing interest in the role of inflammation, oxidative stress, and immune dysregulation in amplifying neuronal injury. These insights have paved the way for novel neuroprotective strategies, including pharmacologic agents such as erythropoietin and melatonin, as well as regenerative approaches like stem cell therapy (6)(9). At the same time, advances in neuroimaging, electrophysiological monitoring, and biomarker discovery are enhancing our ability to diagnose HIE early, assess injury severity, and predict long-term outcomes.

Given the evolving understanding of HIE as a multifaceted, time-dependent process, a comprehensive, integrative approach to its management is essential. This includes not only acute neuroprotection but also long-term surveillance and rehabilitation to address the broad spectrum of neurodevelopmental impairments associated with the condition.

This narrative review aims to provide an updated overview of neonatal hypoxic-ischemic encephalopathy, focusing on its underlying pathophysiological mechanisms, current and emerging neuroprotective strategies, and long-term neurodevelopmental outcomes. By synthesizing

https://doi.org/10.63501/hw12ag67

recent evidence, this review seeks to highlight key advances, identify existing gaps, and outline future directions to improve outcomes for affected infants.

Pathophysiology of Hypoxic-Ischemic Encephalopathy:

Primary Energy Failure

The initial insult in HIE involves reduced cerebral blood flow and oxygen deprivation, leading to impaired oxidative phosphorylation and rapid depletion of adenosine triphosphate (ATP) (4). This energy failure disrupts ion gradients, resulting in cellular depolarization, calcium influx, cytotoxic edema, and neuronal necrosis (5).

Secondary Energy Failure

Following a transient recovery phase, a delayed secondary phase of injury occurs within hours to days. This phase is characterized by:

- Excessive glutamate release (excitotoxicity)
- Intracellular calcium overload
- Generation of reactive oxygen species (ROS)
- Mitochondrial dysfunction
- Activation of apoptotic pathways (4)(6)

This phase represents a critical therapeutic window for neuroprotective interventions.

Tertiary Phase (Chronic Injury)

Recent evidence highlights a prolonged tertiary phase involving persistent inflammation, gliosis, and impaired neurogenesis, contributing to long-term brain injury and neurodevelopmental deficits (7). Chronic microglial activation and epigenetic changes further exacerbate neuronal loss.

Role of Inflammation and Oxidative Stress

Inflammatory cytokines and oxidative stress play central roles in amplifying neuronal injury. Reperfusion injury following restoration of blood flow further worsens cellular damage through oxidative mechanisms (8)(9).

Neuroprotective Strategies

Therapeutic Hypothermia (Standard of Care)

Therapeutic hypothermia (TH) remains the only evidence-based standard therapy for moderate to severe neonatal hypoxic-ischemic encephalopathy. Current protocols involve whole-body or selective head cooling to 33–34°C initiated within 6 hours of birth and maintained for 72 hours, followed by controlled rewarming. The neuroprotective effect of TH is primarily mediated through attenuation of secondary energy failure, reduction of cerebral metabolic demand, suppression of excitotoxic neurotransmitter release, stabilization of mitochondrial function, and inhibition of inflammation and apoptosis.

The efficacy of TH was established through several landmark randomized controlled trials. The CoolCap trial demonstrated a reduction in death or severe disability among infants with moderate encephalopathy treated with selective head cooling (13). Similarly, the NICHD Neonatal Research Network trial showed that whole-body hypothermia significantly reduced the combined endpoint of death or moderate-to-severe disability at 18 months (14). The TOBY trial further confirmed improved survival without neurological disability in cooled infants compared with standard care (15). Subsequent Cochrane meta-analyses demonstrated that TH reduces mortality and major neurodevelopmental disability in survivors, establishing TH as the global standard of care for eligible term and near-term neonates with HIE (16).

Despite these advances, TH provides incomplete neuroprotection. Long-term follow-up studies indicate that approximately 30–50% of treated infants continue to experience adverse outcomes, including cerebral palsy, epilepsy, cognitive impairment, and behavioral dysfunction (12)(15). Moreover, the efficacy of TH in low- and middle-

income countries has been inconsistent, possibly due to delayed initiation, coexisting infection, malnutrition, and differences in neonatal intensive care infrastructure. The HELIX trial notably reported no benefit and potential harm associated with hypothermia in some low-resource settings, highlighting the importance of context-specific implementation strategies (17).

Although TH remains the cornerstone of management, these limitations have accelerated interest in adjunctive neuroprotective therapies targeting complementary injury pathways.

Emerging Neuroprotective Therapies

Erythropoietin (EPO)

Erythropoietin (EPO) has attracted significant interest because of its anti-apoptotic, anti-inflammatory, antioxidant, and neuroregenerative properties. Experimental studies demonstrated that EPO may reduce neuronal death, enhance oligodendrocyte survival, and promote neurogenesis after hypoxic-ischemic injury. Early phase clinical studies also suggested improved neurological outcomes when EPO was combined with therapeutic hypothermia.

However, more recent high-quality evidence has tempered initial enthusiasm. The HEAL trial, a large multicenter randomized controlled trial involving 501 infants with HIE treated with hypothermia, found that high-dose EPO did not significantly reduce death or neurodevelopmental impairment at 22–36 months compared with placebo (18). Additionally, concerns regarding increased serious adverse events were raised. Consequently, although EPO remains biologically promising, current evidence does not support its routine clinical use outside research settings. Ongoing studies are evaluating alternative dosing strategies, timing of administration, and combination approaches.

Melatonin

Melatonin acts as a potent antioxidant and anti-inflammatory agent, reducing oxidative stress-mediated neuronal injury (6).

Allopurinol

Allopurinol acts by inhibiting xanthine oxidase, thereby reducing the generation of reactive oxygen species during reperfusion injury. Preclinical studies suggested that allopurinol may attenuate oxidative stress-mediated neuronal injury when administered shortly after hypoxic exposure.

Nevertheless, clinical evidence remains inconclusive. The ALBINO trial, a large multicenter phase III randomized controlled trial evaluating early allopurinol administration in neonates with suspected perinatal asphyxia, failed to demonstrate a significant reduction in death or severe neurodevelopmental impairment (19). Although subgroup analyses and mechanistic studies continue to explore its potential role, current evidence does not support the routine use of allopurinol as standard neuroprotective therapy in HIE.

Stem Cell Therapy

Umbilical cord blood and mesenchymal stem cells are being explored for their regenerative potential and ability to modulate inflammation (9).

Caffeine and Other Agents

Caffeine citrate and other neuroactive agents are under investigation for their potential to improve cerebral perfusion and reduce injury (6).

Combination Therapies

Given the multifactorial pathophysiology of HIE, combination therapies that simultaneously target multiple injury pathways are increasingly viewed as a necessary strategy to achieve more complete neuroprotection. Therapeutic hypothermia alone primarily attenuates secondary energy failure but

does not fully suppress inflammation, oxidative stress, or tertiary-phase injury processes.

Several combination approaches are currently under investigation. Melatonin combined with hypothermia has shown synergistic antioxidant and anti-inflammatory effects in experimental models, and an ongoing phase III trial (NCT02621944) is evaluating its clinical efficacy. Xenon combined with hypothermia has also demonstrated neuroprotective potential through NMDA receptor antagonism, although clinical studies have produced mixed results regarding long-term benefit. Regenerative approaches such as the COMET trial are exploring the use of umbilical cord blood-derived cell therapy alongside hypothermia to enhance repair and neuroregeneration.

The growing emphasis on multimodal neuroprotection reflects the recognition that HIE evolves through overlapping injury mechanisms extending beyond the immediate post-asphyxia period. Future therapeutic paradigms will likely involve individualized combinations of hypothermia, pharmacologic neuroprotection, immunomodulation, and regenerative therapies.

Long-Term Neurodevelopmental Outcomes

Cognitive and Motor Impairment

Long-term neurodevelopmental impairment remains common among survivors of neonatal HIE despite advances in neonatal intensive care and therapeutic hypothermia. Cerebral palsy represents one of the most severe motor sequelae, particularly among infants with basal ganglia and thalamic injury patterns on MRI. Follow-up studies from the TOBY and NICHD cohorts demonstrated that moderate-to-severe HIE is strongly associated with impaired motor function, reduced IQ scores, executive dysfunction, and learning difficulties during childhood (15)(20).

The severity of neurodevelopmental impairment correlates closely with both the extent and anatomical distribution of brain injury. Watershed-predominant injury patterns are more frequently associated with cognitive and behavioral deficits, whereas deep nuclear injury is strongly associated with motor disability and cerebral palsy. Importantly, even children without overt motor impairment may later demonstrate subtle deficits in attention, processing speed, memory, and academic performance, emphasizing the need for long-term developmental surveillance.

Epilepsy

HIE is a major cause of neonatal seizures and increases the risk of chronic epilepsy due to cortical injury and abnormal neuronal circuitry (1).

Behavioral and Psychiatric Outcomes

Increasing evidence suggests that survivors of neonatal HIE are at elevated risk for long-term behavioral and psychiatric disorders extending beyond traditional motor deficits. Longitudinal follow-up studies have identified increased rates of attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder traits, anxiety, emotional dysregulation, and social communication difficulties among school-aged children with prior HIE exposure (20)(21).

Notably, these impairments may emerge even in children who demonstrate relatively preserved early motor development, suggesting that subtle cortical and network-level injuries may contribute to later neuropsychiatric dysfunction. Van Handel et al. reported that survivors of neonatal encephalopathy frequently exhibit impairments in attention, executive functioning, and behavioral regulation during adolescence, while follow-up analyses from hypothermia trials have demonstrated persistent cognitive and psychosocial vulnerabilities despite improved survival outcomes (21)(22).

These findings highlight the importance of long-term multidisciplinary follow-up that includes

neuropsychological and behavioral assessment in addition to conventional neurological evaluation.

Prognostic Tools

Accurate early prognostication remains essential in HIE to guide therapeutic decision-making, counsel families, and identify infants requiring long-term follow-up. Magnetic resonance imaging (MRI), particularly diffusion-weighted imaging performed during the first week of life, remains one of the most reliable predictors of neurodevelopmental outcome. MRI injury patterns involving the basal ganglia, thalami, posterior limb of the internal capsule, and watershed cortex strongly correlate with later motor and cognitive impairment (23).

Amplitude-integrated electroencephalography (aEEG) is widely used for bedside neurological monitoring and early seizure detection. Systematic reviews have demonstrated that severely abnormal background patterns and delayed normalization of aEEG are associated with increased risk of death and neurodevelopmental disability (23). However, the predictive accuracy of aEEG may be modified by therapeutic hypothermia and sedative exposure.

Biomarker research is also rapidly evolving. Serum neuron-specific enolase (NSE), S100B protein, glial fibrillary acidic protein (GFAP), inflammatory cytokines, and circulating microRNAs have demonstrated potential utility for early risk stratification and prognostication. Although none are currently established as standalone clinical tools, integration of biochemical markers with neuroimaging and electrophysiological monitoring may improve precision-based prognostic assessment in the future.

FUTURE DIRECTIONS:

Future progress in hypoxic-ischemic encephalopathy (HIE) management will depend on earlier diagnosis, precision medicine, and multimodal neuroprotection. Emerging biomarkers such as neuron-specific enolase, S100B, GFAP, and microRNAs may improve early detection and prognostication before irreversible injury occurs. Optimizing therapeutic hypothermia in low- and middle-income countries through affordable technologies and context-specific protocols remains another major priority.

Combination therapies integrating hypothermia with agents such as erythropoietin, melatonin, xenon, and stem cell-based treatments may provide synergistic neuroprotection by targeting multiple injury pathways simultaneously. Regenerative medicine, particularly mesenchymal stem cells and umbilical cord blood-derived cells, also shows promise in promoting neurorepair and neurogenesis.

Advances in neuroimaging, EEG analysis, and artificial intelligence may further enhance early outcome prediction and individualized treatment planning. In addition, recognition of the tertiary phase of brain injury highlights the importance of long-term neurodevelopmental surveillance and interventions targeting chronic neuroinflammation and impaired synaptic plasticity. Finally, multidisciplinary and family-centered care models will be essential to improve long-term functional and psychosocial outcomes for affected children and their families.

CONCLUSION:

Neonatal hypoxic-ischemic encephalopathy remains a major cause of neonatal mortality and long-term neurological disability, driven by a complex cascade of metabolic, inflammatory, and apoptotic injury. Although therapeutic hypothermia has significantly improved outcomes, its benefits are incomplete, and many infants continue to experience adverse neurodevelopmental sequelae (10)(12).

Advances in understanding the evolving phases of brain injury have highlighted new therapeutic windows and opportunities for intervention. Emerging strategies, including adjunctive pharmacologic agents and regenerative therapies, alongside improvements in early diagnosis and

prognostication, offer promising avenues to enhance neuroprotection.

A comprehensive approach that integrates early identification, multimodal treatment, and long-term neurodevelopmental follow-up is essential. Continued research and equitable implementation of effective therapies will be critical to improving outcomes, particularly in resource-limited settings where the burden of HIE remains highest

AI Use Statement: OpenAI ChatGPT-5.5 was used exclusively for language refinement, grammatical editing, and organizational assistance during manuscript preparation. No artificial intelligence tool was used for literature selection, evidence appraisal, data interpretation, synthesis of clinical conclusions, or reference generation. All scientific content, critical analysis, and final manuscript decisions were performed and verified by the authors.

Conflict of Interest: None declared.

Ethical Statement: Not applicable.

Funding: None.

REFERENCES

1. Chakkarapani E, de Vries LS, Ferriero DM, Gunn AJ. Neonatal encephalopathy and hypoxic-ischemic encephalopathy: the state of the art. Pediatric Research. 2025 Mar 24:1-5.
2. Konrad J, Chau V, Selvanathan T. Advances in Neonatal Hypoxic-Ischemic Encephalopathy. Pediatric Clinics. 2025 Oct 1;72(5):939-55.
3. Arnautovic T, Sinha S, Laptook AR. Neonatal hypoxic-ischemic encephalopathy and hypothermia treatment. Obstetrics & Gynecology. 2024 Jan 1;143(1):67-81.
4. Armour EA, Curcio AM, Fryer RH. Neonatal hypoxic ischemic encephalopathy: an updated preclinical and clinical review. OBM Neurobiology. 2020 Jul;4(3):1-5.
5. Yang M, Wang K, Liu B, Shen Y, Liu G. Hypoxic-ischemic encephalopathy: pathogenesis and promising therapies. Molecular Neurobiology. 2025 Feb;62(2):2105-22.
6. Babbo CC, Mellet J, van Rensburg J, Pillay S, Horn AR, Nakwa FL, Velaphi SC, Kali GT, Coetzee M, Masemola MY, Ballot DE. Neonatal encephalopathy due to suspected hypoxic ischemic encephalopathy: pathophysiology, current, and emerging treatments. World Journal of Pediatrics. 2024 Nov;20(11):1105-14.
7. Shu J, Liu L, Yuan M, Ma M, Yang J. Paradigm shifts in neonatal hypoxic-ischemic encephalopathy therapeutics: a four-decade bibliometric exploration of emerging therapeutic dimensions (1985–2024). Frontiers in Pediatrics. 2025 Jul 28;13:1611345.
8. Qin X, Cheng J, Zhong Y, Mahgoub OK, Akter F, Fan Y, Aldughaim M, Xie Q, Qin L, Gu L, Jian Z. Mechanism and treatment related to oxidative stress in neonatal hypoxic-ischemic encephalopathy. Frontiers in molecular neuroscience. 2019 Apr 11;12:88.
9. Chan NH, Hawkins CC, Rodrigues BV, Cornet MC, Gonzalez FF, Wu YW. Neuroprotection for neonatal hypoxic–ischemic encephalopathy: A review of novel therapies evaluated in clinical studies. Developmental Medicine & Child Neurology. 2025 May;67(5):591-9.
10. Moran P, Sullivan K, Zanelli SA, Burnsed J. Single-Center Experience with Therapeutic Hypothermia for Hypoxic–Ischemic Encephalopathy in Infants with< 36 Weeks' Gestation. American Journal of Perinatology. 2024 Sep;41(12):1680-7.
11. Dolan F, Wintermark P. Updates in treatment of hypoxic-ischemic encephalopathy. Clinics in Perinatology. 2025 Jun 1;52(2):321-43.
12. Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, Polin RA, Robertson CM, Thoresen M, Whitelaw A, Gunn AJ. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. The Lancet. 2005 Feb 19;365(9460):663-70.
13. Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, Fanaroff AA, Poole WK, Wright LL, Higgins RD, Finer NN. Whole-body hypothermia for neonates with hypoxic–ischemic encephalopathy. New England

Journal of Medicine. 2005 Oct 13;353(15):1574-84.
14. Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, Kapellou O, Levene M, Marlow N, Porter E, Thoresen M. Moderate hypothermia to treat perinatal asphyxial encephalopathy. New England Journal of Medicine. 2009 Oct 1;361(14):1349-58.
15. Soll RF. Cooling for newborns with hypoxic ischemic encephalopathy. Neonatology. 2013 Nov 1;104(4):260.
16. Thayyil S, Pant S, Montaldo P, Shukla D, Oliveira V, Ivain P, Bassett P, Swamy R, Mendoza J, Moreno-Morales M, Lally PJ. Hypothermia for moderate or severe neonatal encephalopathy in low-income and middle-income countries (HELIX): a randomized controlled trial in India, Sri Lanka, and Bangladesh. The Lancet Global Health. 2021 Sep 1;9(9):e1273-85.
17. Rogers EE, Bonifacio SL, Glass HC, Juul SE, Chang T, Mayock DE, Durand DJ, Song D, Barkovich AJ, Ballard RA, Wu YW. Erythropoietin and hypothermia for hypoxic-ischemic encephalopathy. Pediatric neurology. 2014 Nov 1;51(5):657-62.
18. Maiwald CA, Annink KV, Rüdiger M, Benders MJ, Van Bel F, Allegaert K, Naulaers G, Bassler D, Klebermaß-Schrehof K, Vento M, Guimarães H. Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO): study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III). BMC pediatrics. 2019 Jun 27;19(1):210.
19. Marlow N, Shankaran S, Rogers EE, Maitre NL, Smyser CD, Newborn Brain Society Guidelines and Publications Committee. Neurological and developmental outcomes following neonatal encephalopathy treated with therapeutic hypothermia. In Seminars in Fetal and Neonatal Medicine 2021 Oct 1 (Vol. 26, No. 5, p. 101274). WB Saunders.
20. Van Handel M, Swaab H, De Vries LS, Jongmans MJ. Long-term cognitive and behavioral consequences of neonatal encephalopathy following perinatal asphyxia: a review. European journal of pediatrics. 2007 Jul;166(7):645-54.
21. Gadian DG, Aicardi J, Watkins KE, Porter DA, Mishkin M, Vargha-Khadem F. Developmental amnesia associated with early hypoxic–ischaemic injury. Brain. 2000 Mar 1;123(3):499-507.
22. Rutherford MA, Pennock JM, Counsell SJ, Mercuri E, Cowan FM, Dubowitz LM, Edwards AD. Abnormal magnetic resonance signal in the internal capsule predicts poor neurodevelopmental outcome in infants with hypoxic-ischemic encephalopathy. Pediatrics. 1998 Aug 1;102(2):323-8.
23. van Laerhoven H, de Haan TR, Offringa M, Post B, van der Lee JH. Prognostic tests in term neonates with hypoxic-ischemic encephalopathy: a systematic review. Pediatrics. 2013 Jan 1;131(1):88-98.